Search

Your search keyword '"Mamta K. Jain"' showing total 11 results
Start Over Author "Mamta K. Jain" Journal gastroenterology
11 results on '"Mamta K. Jain"'

1. 742 ACTIVE HBV TRANSCRIPTION AND TRANSLATION PERSIST DESPITE SUPPRESSION OF VIRAL REPLICATION IN HIV/HBV CO-INFECTED PATIENTS RECEIVING DUALLY ACTIVE ANTIRETROVIRAL THERAPY

Author

Atul K. Bhan, Mauricio Lisker-Melman, Mandana Khalili, David E. Kleiner, David Wong, Abdus S. Wahed, Mamta K. Jain, Raymond T. Chung, Richard K. Sterling, Gavin A. Cloherty, Marc G. Ghany, and Mark S. Sulkowski

Subjects
Hepatology, Viral replication, Transcription (biology), business.industry, Gastroenterology, Human immunodeficiency virus (HIV), Medicine, business, medicine.disease_cause, Antiretroviral therapy, Virology
Published
2020

2. 629 CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH MEDICAID AND INDIGENT CARE INSURANCE ARE SIGNIFICANTLY LESS LIKELY TO RECEIVE ANTIVIRAL THERAPY: A MULTI-CENTER ANALYSIS OF FOUR COMMUNITY-BASED SAFETY-NET HEALTH SYSTEMS

Author

Bolin Niu, Mae Thamer, Onkar Kshirsagar, George Therapondos, Robert K. S. Wong, and Mamta K. Jain

Subjects
Community based, Indigent care, medicine.medical_specialty, Hepatology, business.industry, Safety net, Gastroenterology, Antiviral therapy, Virus, Family medicine, Medicine, Center (algebra and category theory), business, Medicaid, Healthcare system
Published
2020

3. Tu1553 – Hepatitis B Virus Patients with Medicaid Or Indigent Care Insurance Have the Lowest Rates of Antiviral Treatment: An Observational Study of Two Urban Safety-Net Health Systems

Author

Mamta K. Jain, Lakshmi Digala, Mae Thamer, Christopher Clark, Onkar Kshirsagar, and Robert J. Wong

Subjects
Hepatitis B virus, Indigent care, medicine.medical_specialty, Hepatology, business.industry, Safety net, Gastroenterology, medicine.disease_cause, Family medicine, medicine, Observational study, Antiviral treatment, business, Medicaid, Healthcare system
Published
2019

4. 625 - The Negative Impact of Diabetes Mellitus on Continued Fibrosis Progression Despite Hepatitis C Virus Treatment is Amplified in the Setting of Obesity

Author

Onkar Kshirsagar, Mamta K. Jain, Christopher Clark, George Therapondos, Robert J. Wong, Mae Thamer, and Mitchell L. Shiffman

Subjects
medicine.medical_specialty, Hepatology, business.industry, Hepatitis C virus, Gastroenterology, medicine.disease, medicine.disease_cause, Obesity, Fibrosis, Internal medicine, Diabetes mellitus, medicine, business
Published
2018

5. Mo1470 - The Relationship of Quantitative Hepatitis B Surface Antigen (QHBSAG) and E Antigen (Qhbeag) Levels to Liver Histology in HBV-HIV Coinfection: Results from the HBV-HIV Cohort Study

Author

Raymond T. Chung, Mamta K. Jain, Abdus S. Wahed, Mark S. Sulkowski, Mauricio Lisker-Melman, Wendy C. King, Mandana Khalili, David Wong, Marc G. Ghany, Richard K. Sterling, and David E. Kleiner

Subjects
HIV Coinfection, Hepatology, Antigen, business.industry, Gastroenterology, Human immunodeficiency virus (HIV), medicine, medicine.disease_cause, Hepatitis b surface antigen, business, Liver histology, Virology, Cohort study
Published
2018

6. Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV)

Author

Mauricio Lisker-Melman, Raymond T. Chung, Mark S. Sulkowski, Abdus S. Wahed, Marc G. Ghany, Mandana Khalili, Richard K. Sterling, David E. Kleiner, David Wong, and Mamta K. Jain

Subjects
Liver disease, Hepatology, business.industry, Gastroenterology, Human immunodeficiency virus (HIV), medicine, Hepatitis B virus HBV, medicine.disease_cause, medicine.disease, business, Virology
Published
2017

7. High Prevalence of Significant Co-Morbidities and Low Rates of Receiving Hepatitis C Virus Treatment among Ethnically Diverse, High Risk, Urban Safety-Net Hospital Populations in California and Texas

Author

Mae Thamer, Mamta K. Jain, Robert J. Wong, Onkar Kshirsagar, Christopher Clark, and Yu-Chi Lapid

Subjects
High prevalence, Hepatology, business.industry, Safety net, Environmental health, Hepatitis C virus, Gastroenterology, medicine, Co morbidity, Ethnically diverse, medicine.disease_cause, business
Published
2017

8. Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV)

Author

Abdus S. Wahed, Raymond T. Chung, Mauricio Lisker-Melman, Mark S. Sulkowski, David Wong, Mandana Khalili, David E. Kleiner, Mamta K. Jain, Richard K. Sterling, and Marc G. Ghany

Subjects
HBsAg, Hepatology, Antigen, business.industry, Gastroenterology, Hepatitis B virus HBV, Human immunodeficiency virus (HIV), Medicine, In patient, business, medicine.disease_cause, Virology, Staining
Published
2017

10. 463 The Impact of HIV Serologic Status on Clinical Presentation, Treatment and Survival in Patients With Hepatocellular Carcinoma

Author

Glen C. Balch, Mamta K. Jain, Amit G. Singal, Madhu Subramanian, Adam C. Yopp, and John C. Mansour

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Human immunodeficiency virus (HIV), medicine.disease, medicine.disease_cause, Serology, Hepatocellular carcinoma, Internal medicine, Medicine, In patient, Presentation (obstetrics), business
Published
2012

11. Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C

Author

Hejun Yuan, William M. Lee, Mamta K. Jain, Corron Sanders, Nahid Attar, and R Kenton Devine

Subjects
Drug, Hepatology, business.industry, media_common.quotation_subject, digestive, oral, and skin physiology, Daidzein, Gastroenterology, Liver failure, food and beverages, Pharmacology, Liver regeneration, chemistry.chemical_compound, genomic DNA, chemistry, Chronic hepatitis, MiR-122, Medicine, In patient, business, media_common
Abstract

function. Daidzein increased BrdU incorporation to ~30% and prevented hyperbilirubinemia in mice subjected to IR+PHX. While all mice survived after PHX, survival decreased to ~13% after IR+PHX. Daidzein increased survival after IR+PHX to ~88%.Conclusion. Suppression of MB after IR+PHX plays an important role in inhibition of liver regeneration and function. MB is a novel therapeutic target to improve the outcome of MLR (NIDDK).

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results